Metraipolis › archive › dc_16adcfae0609

U.S. CDC support to international SARS-CoV-2 seroprevalence surveys, May 2020-February 2022 — Europe PMC PMID:36157894

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/36157894
DOI
10.1371/journal.pgph.0000658
License (as archived)
CC0-1.0
Archived
2026-10-17T08:57:00.655Z
SHA-256 of the archived text
a2c3279f438a7514660fc0e83f9027d7f2ff70bda8a93279db7886ccba999a35
Stable URL of this page
https://metraipolis.com/documento/dc_16adcfae0609

How to cite

U.S. CDC support to international SARS-CoV-2 seroprevalence surveys, May 2020-February 2022 — Europe PMC PMID:36157894 — Europe PMC (en), https://europepmc.org/article/MED/36157894 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_16adcfae0609 (Metraipolis archive dc_16adcfae0609, sha256 a2c3279f438a7514660fc0e83f9027d7f2ff70bda8a93279db7886ccba999a35)
BibTeX
@misc{dc16adcfae0609,
  title = {U.S. CDC support to international SARS-CoV-2 seroprevalence surveys, May 2020-February 2022 — Europe PMC PMID:36157894},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/36157894},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_16adcfae0609; sha256 a2c3279f438a7514660fc0e83f9027d7f2ff70bda8a93279db7886ccba999a35},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/36157894. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

SARS-CoV-2 seroprevalence surveys provide critical information to assess the burden of COVID-19, describe population immunity, and guide public health strategies. Early in the pandemic, most of these surveys were conducted within high-income countries, leaving significant knowledge gaps in low-and middle-income (LMI) countries. To address this gap, the U.S. Centers for Disease Control and Prevention (CDC) is supporting serosurveys internationally. We conducted a descriptive analysis of international serosurveys supported by CDC during May 12, 2020-February 28, 2022, using an internal tracker including data on the type of assistance provided, study design, population surveyed, laboratory testing performed, and status of implementation. Since the beginning of the pandemic, CDC has supported 72 serosurveys (77 serosurvey rounds) in 35 LMI countries by providing technical assistance (TA) on epidemiologic, statistical, and laboratory methods, financial assistance (FA), or both. Among these serosurvey rounds, the majority (61%) received both TA and FA from CDC, 30% received TA only, 3% received only FA, and 5% were part of informal reviews. Fifty-four percent of these serosurveys target the general population, 13% sample pregnant women, 7% sample healthcare workers, 7% sample other special populations (internally displaced persons, patients, students, and people living with HIV), and 18% assess multiple or other populations. These studies are in different stages of implementation, ranging from protocol development to dissemination of results. They are conducted under the leadership of local governments, who have ownership over the data, in collaboration with international partners. Thirty-four surveys rounds have completed data collection. CDC TA and FA of SARS-CoV-2 seroprevalence surveys will enhance the knowledge of the COVID-19 pandemic in almost three dozen LMI countries. Support for these surveys should account for current limitations with interpreting results, focusing efforts on prospective cohorts, identifying, and forecasting disease patterns over time, and helping understand antibody kinetics and correlates of protection.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera).
Pubblicazione: PLOS global public health, 2022 (prima pubblicazione 2022-08-01).
Identificativi: PMID 36157894 · PMCID PMC9490761 · DOI 10.1371/journal.pgph.0000658.
Pagina: https://europepmc.org/article/MED/36157894 — https://doi.org/10.1371/journal.pgph.0000658. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-10-17T08:32:11.935Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.